Tenaya Therapeutics, Inc. — Form 8-K Summary
Reporting date: November 16, 2022; filed November 17, 2022. The filing reports entry into an underwriting agreement for a public equity offering. Tenaya is incorporated in Delaware and its common stock trades on Nasdaq under the symbol TNYA.
Offering and Key Financial Terms
- Tenaya agreed to sell 22,613,307 shares of common stock at a public price of $2.60 per share.
- It also agreed to sell pre-funded warrants to purchase 6,236,693 shares at a public price of $2.599 per underlying share.
- Underwriters will purchase the common stock at $2.444 per share and the pre-funded warrants at $2.443 per underlying share.
- Gross proceeds are expected to be approximately $75.0 million before underwriting discounts, commissions and other offering expenses, assuming no exercise of the over-allotment option.
- The underwriters have a 30-day option to purchase up to an additional 4,327,500 common shares solely to cover over-allotments.
- The offering was expected to close on November 21, 2022, subject to customary closing conditions.
- Each pre-funded warrant has an exercise price of $0.001 per share and is exercisable until exercised in full, including through a cashless exercise feature.
Material Changes Versus the Prior Comparable Period
The filing does not provide comparative revenue, profit, cash flow, margin, debt or liquidity figures. The material transaction disclosed is the planned capital raise, which would increase cash and common-stock-equivalent securities outstanding, subject to closing and warrant exercise.
Guidance, Outlook, Risks and Unusual Items
- Management provided no operating or financial guidance in this filing.
- Completion of the offering, its timing and final terms remain subject to customary closing conditions and market conditions.
- The pre-funded warrants contain beneficial-ownership and voting-power limitations generally set at 9.99%, adjustable by the holder to a level not exceeding 19.99% with advance notice.
- In certain fundamental transactions, warrant holders may receive the securities, cash or other property they would have received upon a hypothetical pre-transaction exercise.
- The offering is being conducted under the company’s effective Form S-3 registration statement.
- The filing incorporates risk factors from Tenaya’s Form 10-Q filed November 10, 2022, including risks related to market conditions and the possibility that the offering may not close on the anticipated terms or at all.
Facts Investors Should Verify
- Whether the offering closed on or around November 21, 2022 and the actual net proceeds received.
- Whether the underwriters exercised any portion of the 4,327,500-share over-allotment option.
- The final number of common shares outstanding after the offering and any subsequent exercise of the pre-funded warrants.
- The use of proceeds and the company’s updated cash runway, liquidity and financing needs in subsequent filings.
- The financial and clinical updates disclosed in the company’s November 10, 2022 Form 10-Q and later reports.